# Pulmed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulmed

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.pulmedpharma.com
- Total disclosed funding: $41M
- Latest round: Series C (Jan 5, 2022)
- Investors on record: 7

## About

Based in Hangzhou, China and established in 2015, Pulmed is a clinical-stage biotechnology company that focuses on discovering, developing, and commercializing transformative inhalation therapies for respiratory diseases. In 2019, it completed a pilot BE study for CXF11. In 2020, it completed pivotal BE study for CXF11. In 2021, it completed a license in deal with Aerami Therapeutics for PAH treatment and the company selected as a quasi-unicorn enterprise in Hangzhou. 

The company provides inhalation products based on two proprietary technology platforms covering powder formulation and inhaler design. The formulation platform used micronization and blending technology and state of art engineered particle formation technology to reach most optimal lung deposition. The device platform with less inhalation flow dependent, and smart with digital communication function, use energy from users' inhalation optimally to disperse bulk powder and to deliver particles to the lung. 

The company plans to develop innovative inhaled drug delivery products, external commercial cooperation and the construction of new production bases.

## Funding rounds

- Series C, Jan 5, 2022 — Fortune Capital
- Series C, Oct 11, 2021, $31M — CMS Asset Management, Lapam Capital, Shenzhen Guozhong Venture Capital, Heda Capital
- Series A, Jan 2, 2018, $8.5M — Kaitai Capital, Delian Capital, Shenzhen Guozhong Venture Capital
- Angel, Apr 1, 2016, $1.5M — Delian Capital

## Investors

- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Angel, Series A
- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Series A
- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Series A, Series C
- CMS Asset Management (https://capitalatlas.ai/funds/cms-asset-management) — Series C
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series C
- Heda Capital (https://capitalatlas.ai/funds/heda-capital) — Series C
- Fortune Capital — Series C